Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir

Journal of Clinical Gastroenterology

Volumn 44, Issue 9, 2010, Pages 653-657

  Jung, Young Kul ^a,b   Kim, Ji Hoon ^b   Lee, Young Sun ^b   Lee, Hyun Jung ^b   Yoon, Eileen ^b   Jung, Eun Suk ^b   Hong, Seung Kwon ^b   Joo, Moon Kyung ^b   Yeon, Jong Eun ^b   Park, Jong Jae ^b   Kim, Jae Seon ^b   Bak, Young Tae ^b   Byun, Kwan Soo ^b  

^a Gachon University   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

chronic hepatitis B; entecavir; hepatitis B e antigen positive; hepatitis B surface antigen; treatment naive

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MALE; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED;

EID: 77957596906     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181d52946     Document Type: Article

References (25)

1. Lok AS, McMahon BJ Chronic hepatitis B. Hepatology. 2007;45:507-539.
2. Buster EH, Flink HJ, Cakaloglu Y, et al Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459-467.
3. Yuen MF, Wong DK, Fung J, et al HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135: 1192-1199.
4. Chen YC, Sheen IS, Chu C.M., et al Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123:1084-1089.
5. Fattovich G, Giustina G, Sanchez-Tapias J, et al Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998;93:896-900.
6. Raimondo G, Allain JP, Brunetto M.R., et al Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652-657.
7. Chen YC, Liaw YF Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis. Hepatology. 2004;40:501; author reply 501-502.
8. Wursthorn K, Lutgehetmann M, Dandri M., et al Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675-684.
9. Chan HL, Wong VW, Tse A.M., et al Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462-1468.
10. European Association for the Study of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
11. Brunetto MR, Moriconi F, Bonino F., et al Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-1150.
12. Moucari R, Mackiewicz V, Lada O., et al Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151-1157.
13. Manesis EK, Hadziyannis ES, Angelopoulou O.P., et al Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther. 2007;12:73-82.
14. Chang TT, Gish RG, de Man R, et al A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
15. Leung N, Peng CY, Hann H.W., et al Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72-79.
16. Deguchi M, Yamashita N, Kagita M., et al Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004;115: 217-222.
17. Sung JJ, Wong ML, Bowden S, et al Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128: 1890-1897.
18. Wong DK, Yuen MF, Ngai V.W., et al One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11:909-916.
19. Marcellin P, Heathcote EJ, Buti M, et al Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455.
20. *. J Viral Hepat. 2010;17:16-22.
21. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337: 1733-1745.
22. Kohmoto M, Enomoto M, Tamori A., et al Quantitative detection of hepatitis B surface antigen by chemiluminescent micro particle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol. 2005;75:235-239.
23. Gish RG, Lau DT, Schmid P, et al A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol. 2007; 102:2718-2723.
24. Ding X, Mizokami M, Yao G., et al Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology. 2001;44:43-47.
25. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17: 643-650.